1,3-二甲基-4-氨基哌啶 | 900642-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1,3-二甲基-4-氨基哌啶
• 英文名称: 1,3-dimethylpiperidin-4-amine
• CAS: 900642-45-7
• 化学式: C₇H₁₆N₂
• mdl: MFCD09035302
• 分子量: 128.217
• InChiKey: WLFDKDVGHUCVFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-chlorophenoxy)-2,2-dimethylpropanoic acid 、 1,3-二甲基-4-氨基哌啶 、 三氟乙酸 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 12.0h， 以76%的产率得到trans-3-(2-chlorophenoxy)-N-(1,3-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide trifluoroacetate
  参考文献：
  名称：

  WO2019169153A5

  摘要：

  公开号：

  WO2019169153A5

文献信息

• [EN] ENANTIOMERICALLY PURE ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION<br/>[FR] DÉRIVÉS ÉNANTIOMÉRIQUEMENT PURS D'ADAMATANE POUR LE TRAITEMENT D'INFECTIONS À FILOVIRUS
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2019018185A1

  公开（公告）日：2019-01-24

  The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. Structure I X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyi, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburgvirus.

  本发明的化合物如一般结构I所示，如下所示，对于治疗丝状病毒感染具有有效性。 结构I中X的选择来自于O和H的群组; R1的选择来自于（C6到C10）芳基和（C2到C9）杂环芳基，而R2的选择来自于（C1到C10）烷基，（C1到C10）烯基，（C1到C10）炔基，（C3到C10）环烷基和（C5到C10）环烯基，而NR3aR3b在规范中被定义。 这些化合物对于治疗丝状病毒感染包括埃博拉病毒和马尔堡病毒具有有效性。
• PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
  申请人：Fink Brian E.

  公开号：US20090048244A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供公式I化合物及其药学上可接受的盐。公式I化合物抑制生长因子受体的酪氨酸激酶活性，如HER1、HER2和HER4，因此使它们有用作抗增殖剂。公式I化合物也适用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• Pyrrolotriazine compounds as kinase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：EP2058314A1

  公开（公告）日：2009-05-13

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了式 I 的化合物 及其药学上可接受的盐类。 式 I 化合物可抑制生长因子受体（如 HER1、HER2 和 HER4）的酪氨酸激酶活性，因此可用作抗增殖剂。式 I 化合物还可用于治疗与通过生长因子受体运行的信号转导通路相关的其他疾病。
• ORGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE AND DISPLAY DEVICE EACH COMPRISING THE ELEMENT
  申请人：Konica Minolta Holdings, Inc.

  公开号：EP3046156A1

  公开（公告）日：2016-07-20

  Disclosed is an organic electroluminescent element which has high luminous efficiency, a low driving voltage, excellent heat resistance, excellent raw stock storability and a long service life.

  本发明公开了一种有机电致发光元件，它具有高发光效率、低驱动电压、优异的耐热性、出色的原材料储存性和较长的使用寿命。
• Piperidinyl-3-(aryloxy)propanamides and propanoates
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US11045457B2

  公开（公告）日：2021-06-29

  Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

  公开了式 1 的化合物、 其中 L、r、s、R5、R6、R7、R9、R10、R11、R12、X1、X2、X3、X4、X13 和 X14 在说明书中定义。本公开还涉及制备式 1 化合物的材料和方法、含有它们的药物组合物，以及它们在治疗与 SSTR4 相关的疾病、失调和病症方面的用途。